|
Benepure Pharmaceutical Co., Ltd.
|
Benepure is a professional producer of Botanical Extract, Pharmaceutical Ingredients and Amino Acids in China, which manufactures Flavonoids products like Hesperidin, Diosmin, Hidrosmoin, Rutin, Naringin, Quercetin, Citrus Bioflavonoids,Troxerutin, Red Clover Extract, Soy Isoflavones over 15 years and has expanded to more products now Green Tea Extracts，Natural Sweeteners, Anthocyanidins & polyphenols, APIs and Amino Acids derivatives.
Product Name: Diosmin
Botanical Name: Citrus aurantium var.amara
Part of Used: nuts
Specification: 90.0-101.0% by HPLC
Appearance: light yellow to white powder
CAS No.:520-27-4
Mol. Formula: C28H32O15
Mol. Weight: 608.54
Description:
Diosmin is a type of plant chemical found mainly in citrus fruits. People use diosmin to make medicine.Diosmin is used for treating various disorders of blood vessels including hemorrhoids,varicose veins, poor circulation in the legs (venous stasis), and bleeding (hemorrhage) in the eye or gums. It is also used to treat swelling of the arms (lymphedema) following breast cancer surgery, and to protect against liver toxicity. It is often taken in combination with hesperidin, another plant chemical.
Benepure is a professional producer of Botanical Extract,Pharmaceutical Ingredients and Amino Acids in China,which manufactures Flavonoids products like Hesperidin,Diosmin, Hidrosmoin, Rutin, Naringin,Quercetin, Citrus Bioflavonoids,Troxerutin, Red Clover Extract, Soy Isoflavones over 15 years and has expanded to more products now Green Tea Extracts，Natural Sweeteners,Anthocyanidins & polyphenols, APIs and Amino Acids derivatives.
|
Send Inquiry
|
|
Xiangbei Welman Pharmaceutical Co., Ltd.
|
It is an oral phlebotropic drug used in the treatment of venous disease, i.e., chronic venous insufficiency (CVI) including spider and varicose veins, leg swelling (edema), stasis dermatitis and venous ulcers. It is also used as a stand-alone or surgical adjunctive therapy in hemorrhoidal disease (HD).
|
Send Inquiry
|
Pharma Sources Insight January 2025
